Large for Gestational Age and Obesity-Related Comorbidities

Related Experiment Video

Updated: Nov 4, 2025

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
05:44

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

Published on: May 17, 2024

816

Yong Hee Hong1, Ji-Eun Lee2

  • 1Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

Journal of Obesity & Metabolic Syndrome
|May 31, 2021
PubMed

Insights

Infants born large for gestational age (LGA) face higher risks of lifelong obesity and metabolic syndrome. Early interventions targeting maternal weight are crucial to prevent LGA births and mitigate these long-term health consequences.

Area of Science:

  • Pediatric Endocrinology
  • Maternal-Fetal Medicine
  • Metabolic Health

Background:

  • Both small for gestational age (SGA) and large for gestational age (LGA) birth sizes are linked to lifelong metabolic issues.
  • Long-term effects of LGA births are under-researched, despite associations with early obesity and metabolic risk.

Purpose of the Study:

  • To investigate the long-term health consequences of large for gestational age (LGA) births.
  • To understand the influence of LGA on later obesity risk for pediatric obesity interventions.

Main Methods:

  • This study reviews existing literature on the long-term outcomes of large for gestational age (LGA) infants.
  • Analysis focuses on the association between LGA status and subsequent obesity and metabolic syndrome development.

Main Results:

  • Infants born large for gestational age (LGA) have an increased risk of developing overweight or obesity in childhood, adolescence, and adulthood.
  • LGA is associated with a higher likelihood of metabolic syndrome later in life and increased risk of giving birth to LGA infants.

Conclusions:

  • Maternal overweight or obesity significantly increases the risk of large for gestational age (LGA) births.
  • Interventions for weight control before and during pregnancy are essential to prevent LGA births and associated lifelong health risks.
  • Special attention is required for diabetic and obese women of childbearing age to initiate lifelong obesity management.

Keywords:
Birth weightComorbidityGestational ageObesity

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

564
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.4K

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
849
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.6K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
43
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
62
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
39